NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
ID: 345364Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345364

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-076.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced the P50 Research Center of Excellence Grant Program, aimed at supporting multidisciplinary research on substance use and addiction. This initiative seeks to establish research centers that will conduct innovative studies, mentor new investigators, and serve as national resources for educational outreach in the field of drug abuse research. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with funding available for projects not exceeding $10 million over a maximum period of five years. Key deadlines for application submissions begin on August 25, 2023, with the final submission date set for September 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-076-Full-Announcement.html
    PAR-23-076.html
    The National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA) has released a funding opportunity announcement for the P50 Research Center of Excellence Grant Program. This initiative aims to support multidisciplinary research on substance use and addiction, including its intersection with HIV. The centers are expected to foster innovative science, mentor new investigators, and serve as national resources to enhance educational outreach. Applications are invited from various eligible organizations, including higher education institutions, nonprofits, and government entities, with budgets not exceeding $10 million for a maximum project period of five years. Key submission dates start on August 25, 2023, with deadlines for application submissions occurring periodically up to September 25, 2025. Applicants must adhere to strict guidelines and include a Plan for Enhancing Diverse Perspectives to ensure inclusivity and effectiveness in research. Each center should exhibit scientific innovation, coordination among research projects, and potential to become a valuable resource in the substance use research community, ultimately influencing methods and practices within the field.
    Similar Opportunities
    NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) to enhance research on substance use, addiction, and HIV through collaborative efforts among investigators. This program aims to integrate diverse new and early career researchers, particularly from underrepresented backgrounds, to develop innovative approaches and interdisciplinary projects that transform the scientific research landscape. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and government entities, with a maximum project period of five years and a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested parties should note that the application deadline is November 17, 2025, and can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a cooperative agreement. This initiative aims to provide technical development support for researchers working on new digital therapeutics for SUD, facilitating the transition from initial ideas to market-ready products. The program addresses the critical gap in early translational funding and aims to enhance the landscape of treatment options for substance use disorders by mentoring and educating researchers in formal product development. The maximum funding amount is $1.9 million per year, with applications accepted until November 13, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-056.html.
    Providing Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and Addiction Scientific Workforce (R25 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Providing Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and Addiction Scientific Workforce (R25 Clinical Trials Not Allowed)." This initiative aims to support educational activities that promote diversity in the biomedical and behavioral sciences, particularly focusing on substance use and addiction research, by encouraging applications from institutions committed to underrepresented groups. The program seeks to develop a diverse pool of researchers through mentorship and educational activities tailored to various career stages, with a budget request limit of $250,000 in direct costs annually for up to five years. Interested applicants must submit their proposals by 5:00 PM local time on November 13, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is inviting applications for Program Project Grants (P01 Clinical Trial Optional) aimed at fostering collaborative, multidisciplinary research on substance use disorders. Applicants must propose a minimum of three interrelated research projects that demonstrate scientific and administrative synergy under a unifying theme, addressing critical issues such as neuroscience, genetics, behavior, prevention, treatment, and health services related to substance use. This funding opportunity emphasizes inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) and encouraging participation from underrepresented groups, with a maximum project duration of five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by January 7, 2026.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)." This program aims to enhance research education in substance use and substance use disorder (SUD) among clinical researchers and clinicians by supporting innovative educational activities that focus on research experiences and skills development. The initiative is crucial for addressing the urgent need for a well-qualified workforce to combat SUD and related health issues, targeting individuals in clinically focused careers or training. Eligible applicants include various institutions and organizations, with funding available up to $350,000 annually for a maximum of five years. The application deadline is November 15, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions." This initiative invites R01 applications aimed at conducting impactful research to address disparities in substance use and addiction outcomes among racial and ethnic minority populations, emphasizing community engagement and collaboration with community organizations. The program is part of NIDA's broader Racial Equity Initiative, which seeks to improve health equity and reduce health disparities, with approximately $2 million anticipated for funding across multiple related announcements. Interested applicants, particularly from minority-serving institutions, must submit proposals by November 14, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.